SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-044746
Filing Date
2024-05-17
Accepted
2024-05-17 16:05:47
Documents
15
Period of Report
2024-05-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0206421-8k_tffpharma.htm   iXBRL 8-K 31283
2 AT THE MARKET OFFERING AGREEMENT DATED AS OF MAY 17, 2024 BETWEEN THE COMPANY AN ea020642101ex1-1_tffpharma.htm EX-1.1 212661
3 OPINION OF GREENBERG TRAURIG, LLP ea020642101ex5-1_tffpharma.htm EX-5.1 7907
  Complete submission text file 0001213900-24-044746.txt   484703

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tffp-20240517.xsd EX-101.SCH 3018
5 XBRL LABEL FILE tffp-20240517_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE tffp-20240517_pre.xml EX-101.PRE 22361
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0206421-8k_tffpharma_htm.xml XML 3788
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 24959581
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)